-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Neutral on Biogen, Raises Price Target to $196

Benzinga·04/30/2026 13:07:24
Listen to the news
Wedbush analyst Laura Chico maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $191 to $196.